Biotech Support Group

3Scan is turning tissue biology and histopathology into data science, giving researchers the insights they need to break new ground.

A one-stop shop for digital and computational pathology, 3Scan’s KESM produces digital 3D tissue models with micron-scale resolution at 400 times the throughput of traditional microscopes.

3Scan’s data platform enables quantitative image analysis of diseases like cancer, Parkinson’s, Alzheimer’s, and Huntington’s, opening up the potential for new diagnostic and therapeutic solutions.
Founded by Todd Huffman, Megan Klimen, Matthew Goodman, and Cody Daniel in San Francisco in 2011, 3Scan’s team of engineers, biologists and data-scientists is expanding its work into a suite of digital tools that will allow instant identification and classification of histopathologic features and tissue structures.

Agere is a global leader in bioavailability enhancement and cGMP services. Our comprehensive formulation design and development capabilities leverage Agere's Quadrant 2 solubilization formulation platform. Quadrant 2 empowers formulation development to efficiently explore a broader design space. Adhering to quality by design (QbD) guidelines de-risks results to achieve your target product profile.

All client services -- from formulation through clinical trials materials manufacturing -- are customized per API and done on a fee-for-service basis.

Formulation Development
• Formulation design and development
• Solubilization formulation expertise
• Innovative analytical technologies
• Materials science and characterization
• Computational modeling

cGMP Manufacturing
• Spray drying
• Tablets
• Capsules
• Inhalation powders
• Topical dosage forms

cGMP Analytical
• Full support for manufacturing and release testing
• Method development and transfer
• Method qualification/validation
• Full stability suite of services

EMAIL: info@agerepharma.com or careers@agerepharma.com

Aurora Fine Chemicals is a privately held company that was founded in 1990. As a chemicals R&D supplier we offer chemicals for R&D, drug discovery service, compound libraries and custom synthesis. We have one of the largest collections of 18.1 mln. chemicals available in stock and our docking software delivers hits/leads of very high quality in short time.

Our staff consists of highly qualified individuals with Bsc, Msc and Ph.D. degrees in chemistry, as well as excellent laboratory technicians. In our Molecular Modeling Group are professionals specializing in computational drug design. They possess many years experience of working in the chemistry of heterocycles, carbohydrates, nucleosides and elemental organic compounds. Aurora has significant expertise in synthesis of all types R&D chemicals for drug discovery like small molecules, natural products and peptides. Parallel synthesis with well-designed, targeted and fragment-based libraries is the favored approach to lead optimization. Rational design is the strategy for projects driven by structural biology, such as enzyme inhibitors or protein interactions.

We own a large library of 18.1 million stocked compounds for R&D. Our substances are used in many research labs all over the world. We offer structures for biochemical and chemical research. Our products are applied in pharmaceutical development, diagnosis, and in chemical production.

Several laboratories for synthesis with modern equipment such as reactors, autoclaves, thermostats and hydrogenation equipment are available.

Intermediates and final products are analyzed by GC, HPLC, IR, NMR, MS, elemental analysis, atom-absorption analysis and crystallographical methods.

The main advantage of Aurora's own software is the quality of the underlying physical models. Aurora's software derives molecular properties from first principles based on direct models using advanced quantum mechanical analysis of molecular interactions and thermodynamics.

Confluence Discovery Technologies, a development service company, can help in many phases of the discovery process based on its extensive experience in drug discovery and clinical development. Our proven experience with the discovery and development process coupled with the high-tech approach used by our experts makes Confluence Discovery Technologies your affordable on-shore contract research firm. Our highly trained scientists operate a state-of-the-art laboratory to support Cell and Molecular Biology, Biochemistry / Enzymology, Biomarker Development & Testing, Immunology, In Vivo Efficacy Models, Medicinal, Computational, and Bioanalytical Chemistry, and Project Management in order to make your project a success.

Productivity is a function of experience, expertise and equipment. Confluence Discovery Technologies provides the flexibility and resources necessary to maximize your research initiatives.



• Providing services spanning from one time consultation through independently driving a drug discovery program



• Complete medicinal chemistry design/synthesis, biochemical testing, cell biology testing

• Biomarker assay development

• Project leadership

• Effective decision making

• Innovative, focused and milestone-driven projects



Industry Leading Strength in Mechanistic Enzymology

• Lead series prioritization

• Inhibitor mechanism characterization

• Real vs artifact determination



Skilled Assay Development, Validation and Execution

• Multiple formats, readouts, validation, comparisons

• Data reduction experts

• HTS format experience

Cyclica is the partner of choice for data-driven drug discovery. We advance molecules that embrace the complexity of the disease.

Our computational approach to polypharmacology is unique in the industry. We use a proteome-wide lens to evaluate multiple novel and rare on and off-target interactions simultaneously.

We’re also the only company of our kind that integrates science to advance molecules downstream. A structure-based view keeps our work accountable to biology, chemistry, physics, and genomics.

To learn more about Cyclica and how we partner, please visit www.cyclicarx.com